For instance, PD-L1 expression and TMB together may be able to more accurately predict the response to pembrolizumab in a variety of solid tumors, including HNSCC, according to a study by Cristescu et al. [106]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.